

Activity Outline
Topics in Public Health: Electronic Nicotine Delivery Systems: An Overview
March 22, 2019
Webinar

Activity Coordinator
Ashlee Januszewicz
Ashlee.Januszewicz@fda.hhs.gov

Series Description

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

Lecture Description

Tobacco use among youth and young adults in any form, including Electronic Nicotine Delivery Systems (ENDS), is not safe. In recent years, ENDS use by youth and young adults has increased to epidemic levels and has become a public health crisis. Electronic Nicotine Delivery Systems are now the most commonly used nicotine product among youth in the United States. The presentation gives a general overview of ENDS addressing its history, epidemiology, statistics, ENDS construction, safety (health effects, adverse effects, and toxicology), flavoring, accessibility, advertising, JUULing, and "USPHS Nicotine Cessation Training for Youth and Young Adults."

References

- Wang TW, Gentzke A, Sharapova S, et al. Tobacco Product Use Among Middle and High School Students – United States, 2011-2017. MMWR Morb Mortal Wkly Rep. 2018; 67:629–33. (Original Data Source: NYTS 2017)
- Villanti AC, Johnson AL, Ambrose BK, et al. Use of flavored tobacco products among U.S. youth and adults; findings from the first wave of the PATH Study (2013-2014).
- Toxics. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606648/> 2016 Dec; 4(4): 29.

Series Objectives

- Describe scientific evidence supporting the HHS Initiatives, Surgeon General Priorities or any other public health concern
- Explain the multi-disciplinary approach in addressing public health issues
- Identify public health concerns.
- Identify ways Public Health Professionals can impact public health issues.

Learning Objectives After completion of this activity, the participant will be able to:

- Discuss the rapidly changing patterns of e-cigarette use among youth and young adults.
- Assess the health effects of using ENDS.
- Describe strategies that tobacco companies use to recruit our nation's youth and young adults to try ENDS.

Target Audience

This activity is intended for physicians, pharmacists, nurses, and other public health medical professionals interested in learning more about the initiatives other advances in public health.

Agenda

Lecture 1 March 22, 2019

Time	Topic	Speaker
2:00 - 3:00 PM	Electronic Nicotine Delivery Systems: An Overview	Thomas Addison Jing Li, PharmD

Continuing Education Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-19-014-L04-P, and ACPE Universal Activity Number JA0002895-0000-19-014-L04-T for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

CPH

Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Pharmacists will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

- ▣ Addison, Thomas, Pharmacist, Phoenix Indian Medical Center - nothing to disclose
- ▣ Li, Jing, PharmD, Specialty Pharmacy Manager, USPHS/Indian Health Service - nothing to disclose

Planning Committee

- ▣ Alu, Susan, Pharm.D., Clinical Pharmacist, U.S. Public Health Service - nothing to disclose
- ▣ Begansky, Stephanie, PharmD, Program Coordinator, FDA - nothing to disclose
- ▣ Birch-Smith, Postelle, PharmD - nothing to disclose
- ▣ Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS - nothing to disclose

- ▣ CHIN, EDWARD, Medical Officer, DNDP - nothing to disclose
- ▣ Camilli, Sara, PharmD, , BCPS, Associate Director, FDA/CDER/OSE/DPV II - nothing to disclose
- ▣ Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Januszewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/OU DLC - nothing to disclose
- ▣ Khatri, Sadhna, PharmD, MPH, MS, MEd, Regulatory Officer, FDA/CDER/OCD/PASE - nothing to disclose
- ▣ La, Thang, PharmD, MPH, Central Triage Unit supervisor, FDA/CDER/OSE/RSS - nothing to disclose
- ▣ Leung, Tamy, PharmD, MPH, BCPS, Accountable Care Organization Coordinator, Centers for Medicare and Medicaid - nothing to disclose
- ▣ Lucero, Karly, RN, DNP, MSN/eD, CCHP, Regional Field Medical Coordinator, DHS - nothing to disclose
- ▣ McClain, Rena, PharmD, CMS - nothing to disclose
- ▣ Nabavian, Sadaf, Senior Regulatory Project Manager, FDA - nothing to disclose
- ▣ WAGNER, LINDSAY, PharmD, Team Leader, FDA - nothing to disclose

CE Consultation and Accreditation Team

- ▣ Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

Registration Fee and Refunds

Registration is complimentary, therefore refunds are not applicable.